Abbott Laboratories (ABT): Alyeska Investment Group, L.P. reduced its stake -466K shares
Alyeska Investment Group, L.P. reduced its stake in Abbott Laboratories, per its Q4 2024 13F.
- 583K
- Shares reported · -466K vs prior quarter
- 0.25%
- Disclosed portfolio weight
- $65.9M
- Reported value
- Holdings as of
- Dec 31, 2024
- Filed
- Feb 14, 2025
What stands out in this filing
- 1,048,483 shares in Q3 2024, 582,713 now (−44.4% in share count).
- Reported at $65.9M, 0.25% of the portfolio value in this 13F filing.
- 62 other tracked managers reported the same kind of change for Q4 2024.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 11, 2024CongressDisclosed partial sale of ABT — reported range $15,001 - $50,000
- Dec 16, 2024CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jan 6, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jan 8, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jan 15, 2025Congress · 1 personMembers of Congress: 3 sales
- Jan 28, 2025InsiderOfficer sold ~$337K of ABT shares in the open market
- Jan 28, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jan 29, 2025InsiderOfficer sold ~$16.9M of ABT shares in the open market
- Jan 29, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jan 30, 2025Insider · 2 peopleInsiders: 2 sales (~$10.5M)
- Feb 5, 2025InsiderCEO sold ~$37.4M of ABT shares in the open market
- Feb 13, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
What came next
- Feb 24, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- Mar 3, 2025Insider · 5 peopleInsiders: 5 sales (~$549K)
- Mar 3, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Mar 6, 2025InsiderOfficer sold ~$12.2M of ABT shares in the open market
- Mar 6, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- Mar 7, 2025InsiderOfficer sold ~$27K of ABT shares in the open market
- Mar 18, 2025FDARecall: Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-01 Software Version: All software versions Product Description: CELL-DYN Ruby…
- Mar 18, 2025FDARecall: Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-10 Software Version: All software versions Product Description: CELL-DYN Ruby…
- Mar 18, 2025FDARecall: Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-13 Software Version: All software versions Product Description: CELL-DYN Ruby…
- Mar 18, 2025FDARecall: Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 04U42-84 Software Version: All software versions Product Description: CELL-DYN Ruby
- Mar 18, 2025FDARecall: Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-03 Software Version: All software versions Product Description: CELL-DYN Ruby…
- Mar 20, 2025FDARecall: The Alinity m System is designed to automate the steps for nucleic acid testing. Model Numbers included in this recall are 08N53-001, 08N53-002, and 08N53-032…
- Mar 20, 2025Congress · 1 personMembers of Congress: 2 purchases
- Mar 24, 2025FDAFDA device clearance: Alinity m BKV
- Apr 4, 2025FDAFDA device clearance: JETi Hydrodynamic Thrombectomy System
- Apr 21, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Apr 25, 2025FDAFDA device clearance: Amulet Steerable Delivery Sheath
- Apr 28, 2025FDARecall: Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the si…
- Apr 28, 2025FDARecall: Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List Number 09N79-090, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) tes…
- Apr 30, 2025InsiderDirector sold ~$337K of ABT shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Abbott Laboratories
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.
How this filing works
Explore the data
Common questions
What does this filing report about Abbott Laboratories (ABT) stock?
Alyeska Investment Group, L.P. reduced its stake in Abbott Laboratories, per its Q4 2024 13F. Now 583K shares, $65.9M reported value, 0.25% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2024. Filed: Feb 14, 2025.
What stands out in this filing?
1,048,483 shares in Q3 2024, 582,713 now (−44.4% in share count). Reported at $65.9M, 0.25% of the portfolio value in this 13F filing. 62 other tracked managers reported the same kind of change for Q4 2024.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Abbott Laboratories recently?
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.
Does this mean ABT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Abbott Laboratories
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 6, 2026
- SEC Form 144Nov 5, 2026
- House Clerk periodic transaction reportOct 30, 2026
- House Clerk periodic transaction reportOct 27, 2026
- House Clerk periodic transaction reportOct 12, 2026
Everything OQRO holds on this company is on its ABT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
